GRN Gene Therapy（Eli Lilly And Company）

N/A

Report date: 2026/02/09 20:01:27

Base Information

Drug NameGRN Gene Therapy（Eli Lilly And Company）
Drug Alias NamePR-006LY3884963
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV9 vector
Mechanisms of ActionProgranulin gene transference
TargetsProgranulin
Therapy Area/IndicationsFrontotemporal Dementia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesAustralia +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesPrevail Therapeutics IncEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsFrontotemporal Dementia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A